Cost Effectiveness of Inhaled Mannitol (Bronchitol ® ) in Patients with Cystic Fibrosis
ConclusionBenchmarked against an implicit Australian willingness-to-pay threshold for life-threatening diseases, our model suggests inhaled mannitol provides a cost-effective addition to best supportive care in patients with cystic fibrosis, irrespective of concomitant dornase alfa use.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Australia Health | Cystic Fibrosis | Health Management | Lung Transplant | Pulmozyme | Study | Transplants